Hemophilia B is a genetic bleeding disorder in which the blood is missing or low on a specific protein needed to form clots. It affects roughly 1 in 30,000 male births worldwide, making it about one-fifth as common as its better-known relative, hemophilia A. The missing protein is called factor IX, one of several clotting factors the liver produces to help stop bleeding after an injury.
How Blood Clotting Goes Wrong
When you cut yourself or bruise a blood vessel, your body launches a chain reaction of clotting proteins to seal the damage. Factor IX is a key link in that chain. It works within what’s called the intrinsic pathway, a series of steps triggered when blood contacts damaged tissue inside a vessel. Factor IX activates other proteins downstream, ultimately producing a mesh of fibrin that holds a clot together.
Without enough factor IX, the chain stalls. Platelets still arrive and form an initial plug, but the fibrin mesh that reinforces it never fully forms. The result is bleeding that starts normally but doesn’t stop the way it should, or restarts after it seemed to have stopped.
Severity Levels
Not everyone with hemophilia B experiences the same degree of bleeding. Severity depends on how much factor IX activity remains in the blood, measured as a percentage of normal levels:
- Severe: Less than 1% of normal factor IX. Spontaneous bleeding into joints and muscles can occur without any obvious injury.
- Moderate: 1% to 5%. Bleeding episodes happen with minor trauma and occasionally spontaneously.
- Mild: Greater than 5% but less than 40%. Bleeding is typically only a problem after surgery, dental work, or significant injury. Some people with mild hemophilia B don’t know they have it until a medical procedure triggers unusual bleeding.
Interestingly, research suggests that hemophilia B may produce a somewhat milder bleeding tendency than hemophilia A at the same factor level. The gene responsible for factor IX is smaller and structurally simpler than the gene for factor VIII (the protein missing in hemophilia A), and a higher proportion of hemophilia B mutations are the type that leave some residual clotting function intact.
How It’s Inherited
The gene for factor IX sits on the X chromosome. Because males have only one X chromosome (paired with a Y), a single defective copy of the gene is enough to cause hemophilia B. Females have two X chromosomes, so a working copy on one X can usually compensate for a faulty copy on the other. This is why hemophilia B overwhelmingly affects males, while females are typically carriers.
If a mother carries the hemophilia gene, each son has a 50% chance of inheriting it and having hemophilia B. Each daughter has a 50% chance of becoming a carrier herself. A father with hemophilia B passes his X chromosome to every daughter, making all of them carriers, but he passes his Y chromosome to sons, so none of his sons will inherit the condition from him.
The birth prevalence is roughly the same across all countries and ethnic groups, likely because the gene has a high rate of spontaneous new mutations. About one-third of cases appear in families with no prior history of the disorder.
Symptoms and Joint Damage
The hallmark of hemophilia B is bleeding that is prolonged or difficult to stop. For people with severe disease, the most common and damaging symptom is bleeding into joints, called hemarthrosis. The knees, ankles, and elbows are the joints most frequently affected. An acute joint bleed causes intense pain and swelling as blood fills the joint capsule and pressure builds. Left untreated, repeated bleeds into the same joint can destroy cartilage and bone, leading to chronic pain and loss of mobility by early adolescence.
A “target joint” is one that has bled four or more times in six months. About 33% of people with severe hemophilia develop at least one target joint, compared to roughly 19% with moderate disease and 5% with mild. In patients who receive preventive treatment (prophylaxis), the ankle has become the most common site of bleeding, overtaking the knee.
Beyond joints, common bleeding problems include deep muscle bruises, prolonged bleeding from cuts or after dental procedures, blood in the urine, and in rare but serious cases, bleeding inside the skull. Soft tissue bruising that seems out of proportion to minor bumps is often one of the first signs noticed in young children.
How It’s Diagnosed
Diagnosis starts with blood tests that measure how long it takes your blood to clot. A screening test called an activated partial thromboplastin time (aPTT) is often prolonged in hemophilia B, while other clotting tests come back normal. The confirmatory step is a factor IX activity assay, which measures exactly how much functional factor IX is circulating in your blood. That percentage determines whether the condition is classified as mild, moderate, or severe.
Genetic testing can identify the specific mutation in the factor IX gene, which is useful for confirming the diagnosis, identifying female carriers, and prenatal testing in families with a known history.
Treatment Options
The foundation of hemophilia B treatment is replacing the missing factor IX. Replacement products come in two forms: concentrates purified from donated human plasma, and recombinant versions manufactured in a laboratory without using human blood. Both are given by injection into a vein, either on a regular schedule to prevent bleeds (prophylaxis) or on demand when a bleed occurs.
How often you need infusions depends on the product. Standard factor IX concentrates may need to be given two or three times a week. Extended half-life products last longer in the bloodstream and can reduce the frequency to once a week or less, which makes a meaningful difference in daily life, especially for children.
One complication to be aware of: about 3 in 100 people with hemophilia B develop antibodies, called inhibitors, that attack the replacement factor IX and make it ineffective. This rate is much lower than in hemophilia A, where inhibitors develop in 25% to 30% of severe cases. The lower inhibitor risk in hemophilia B is thought to be related to the smaller, simpler structure of the factor IX protein, which gives the immune system fewer targets to react against. When inhibitors do develop, treatment becomes significantly more complex.
Gene Therapy
Gene therapy represents a fundamentally different approach. Instead of replacing the missing protein repeatedly, it delivers a working copy of the factor IX gene directly into liver cells so the body can produce its own factor IX. The FDA has approved a gene therapy product (marketed as Beqvez, made by Pfizer) for adults with moderate to severe hemophilia B who are on prophylaxis or who have experienced life-threatening or repeated serious bleeding episodes. It is given as a single intravenous infusion.
Not everyone is eligible. Patients must first be tested for antibodies against the viral shell used to deliver the gene, since pre-existing immunity can block the therapy from working. For those who qualify, the goal is to raise factor IX levels enough to reduce or eliminate the need for regular infusions, though individual responses vary and long-term durability is still being tracked in follow-up studies.
Living With Hemophilia B
With modern treatment, most people with hemophilia B lead active lives. Prophylactic factor replacement, started early in childhood, has dramatically reduced the joint damage that once defined severe hemophilia. Physical activity is encouraged, though contact sports carry higher risk and require careful planning with a treatment team.
Practical considerations include learning to self-infuse factor IX (many families learn this for home treatment), wearing medical identification, and coordinating with medical providers before any surgery or dental procedure. Joint health is a lifelong priority. Regular physical therapy and staying active help protect joints by building the muscle strength that supports them.